Pay in 4 interest-free payments of $25.00 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
PR-104A is metabolized under hypoxia by the 1-electron NADPH:cytochrome P450 oxidoreductase
CALP3 causes dose-dependent inhibition of apoptosis (IC50=33
and can be used in the treatment of various diseases
reducing capabilities and Fe2+ chelating effects
It was developed in Spain by FAES Farma
TAK-659 3992 PR-104A is metabolized under hypoxiaTAK 659 is a highly potent, selective, reversible and orally available dual inhibitor of spleen tyrosine kinase (SYK) and fms related tyrosine kinase 3 (FLT3), with an IC50 of 3. 2 nM and 4. 6 nM for SYK and FLT3, respectively. TAK 659 induces cell death in tumor cells but not in nontumor cells, and with potential for the treatment of chronic lymphocytic leukemia (CLL). Product information CAS Number: 1312691 33 0 Molecular Weight: 344. 39 Formula: